Distribution of Immunophenotype Among 908 Cases of Childhood ALL Studied for MyAg Coexpression and Reactivity to Each MyAg
| . | No. of Cases . | MyAg+ALL . | H-ALL . | CD15 . | CD65 . | CD33 . | CD13 . | CD14 . | CD11b . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | (%) . | No. . | (%) . | No. . | (%) . | No. . | (%) . | No. . | (%) . | No. . | (%) . | No. . | (%) . | No. . | (%) . | ||
| Pre-pre–B ALL | 29 | 11 | (38) | 8 | (27.6) | 6 | (20.6) | 6 | (20.6) | 3 | (10.3) | 2 | (6.8) | 2 | (6.8) | 3 | (10.3) |
| Common ALL | 572 | 178 | (31) | 50 | (8.7) | 27 | (4.7) | 34 | (5.9) | 84 | (14.6) | 88 | (15.3) | 31 | (5.4) | 37 | (6.4) |
| Pre-B–ALL | 185 | 67 | (36.2) | 26 | (14) | 20 | (10.8) | 23 | (12.4) | 31 | (16.7) | 37 | (20.0) | 11 | (5.9) | 12 | (6.4) |
| T-ALL | 122 | 35 | (28.6) | 10 | (8) | 8 | (6.5) | 13 | (10.6) | 12 | (9.8) | 15 | (12.2) | 5 | (4.0) | 12 | (9.8) |
| Total | 908 | 291 | (32) | 94 | (10.3) | 61 | (6.7) | 76 | (8.3) | 130 | (14.3) | 142 | (15.6) | 49 | (5.3) | 64 | (7.0) |
| . | No. of Cases . | MyAg+ALL . | H-ALL . | CD15 . | CD65 . | CD33 . | CD13 . | CD14 . | CD11b . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | (%) . | No. . | (%) . | No. . | (%) . | No. . | (%) . | No. . | (%) . | No. . | (%) . | No. . | (%) . | No. . | (%) . | ||
| Pre-pre–B ALL | 29 | 11 | (38) | 8 | (27.6) | 6 | (20.6) | 6 | (20.6) | 3 | (10.3) | 2 | (6.8) | 2 | (6.8) | 3 | (10.3) |
| Common ALL | 572 | 178 | (31) | 50 | (8.7) | 27 | (4.7) | 34 | (5.9) | 84 | (14.6) | 88 | (15.3) | 31 | (5.4) | 37 | (6.4) |
| Pre-B–ALL | 185 | 67 | (36.2) | 26 | (14) | 20 | (10.8) | 23 | (12.4) | 31 | (16.7) | 37 | (20.0) | 11 | (5.9) | 12 | (6.4) |
| T-ALL | 122 | 35 | (28.6) | 10 | (8) | 8 | (6.5) | 13 | (10.6) | 12 | (9.8) | 15 | (12.2) | 5 | (4.0) | 12 | (9.8) |
| Total | 908 | 291 | (32) | 94 | (10.3) | 61 | (6.7) | 76 | (8.3) | 130 | (14.3) | 142 | (15.6) | 49 | (5.3) | 64 | (7.0) |